Author

C. N. Smith

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. S. Blackburn· 2 shared B. G. Patty· 1 shared D. Deredge· 1 shared D. Lee· 1 shared D. R. Rivas· 1 shared K. Kihn· 1 shared K. M. Chow· 1 shared K. V. Korotkov· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

J. S. Blackburn

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Development and validation of nanobodies specifically targeting the oncogenic Phosphatase of Regenerating Liver-3 (PRL-3)

C. N. Smith, K. Kihn, Z. A. Williamson, Y. Chernyavskyay, K. M. Chow, L. B. Hersh, K. V. Korotkov, D. Deredge, J. S. Blackburn

This paper develops and validates nanobodies that specifically target PRL-3, showing high specificity over PRL-1 and PRL-2 and providing tools to study PRL-3 function in cancer.

bioRxiv · Oct 2, 2020 · PreprintBiochemistry

A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3)

D. R. Rivas, M. V. C. Dela Cerna, C. N. Smith, B. G. Patty, D. Lee, J. S. Blackburn

The paper screens FDA-approved drugs to identify inhibitors of PTP4A3 (PRL-3), finding five specific inhibitors and two broad inhibitors that block PRL-3-induced migration without affecting cell viability.

bioRxiv · May 24, 2020Cancer Biology